• Home /
  • Recombinant Human TNF-alpha Variant

Recombinant Human TNF-alpha Variant

Molecule:

TNF-alpha

Synonyms:

DIF, TNFA, TNFSF2, TNF-alpha, TNF-α, TNF

Species:

Human

Cat. No.:

CSI20108B pdf (datasheet)

Quantity/Size:

50 μg

Price:

$275.00 BUY

Description:

Recombinant Human TNF-alpha Variant is a single non-glycosylated polypeptide chain containing 151 amino acids. Compared with the wild-type, this TNF-alpha Variant has an amino acid sequence (a.a.) deletion from a.a. 1-7, and the following a.a. substitutes Arg8, Lys9, Arg10 and Phe157, which are proven to have more activity and with less inflammatory side effect in vivo.

Background: The clinical use of the potent antitumor activity of TNF-alpha has been limited by the proinflammatory side effects including fever, dose-limiting hypotension, hepatotoxicity, intravascular thrombosis, and hemorrhage. Designing clinically applicable TNF-alpha mutants with low systemic toxicity has been an intense pharmacological interest. Human TNF-alpha, which binds to the mouse TNF-R55 but not to the mouse TNF-R75, exhibits retained anti-tumor activity and reduced systemic toxicity in mice compared with moue TNF-alpha, which binds to both mouse TNF receptors. Based on these results, many TNF-alpha mutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines in vitro, and exhibited lower systemic toxicity in vivo.

Data PDF:

CSI20108

Source:

E. coli

Molecular Weight:

~16.9 kDa

Formulation:

Lyophilized from a 0.2 µm sterile filtered solution of PBS, pH 7.0.

Purity:

>98 % by SDS-PAGE and HPLC analyses.

Biological Activity:

Fully biologically active when compared to standard. The ED50 as determined by a cytotoxicity assay using murine L929 cells is less than 0.01 ng/ml, corresponding to a specific activity of > 1.0 × 108 IU/mg in the presence of actinomycin D.

Endotoxin Level:

Less than 1 EU/μg of rHu TNF-α/TNFSF2, Variant as determined by LAL method.

Amino Acid Sequence:

MRKRKPVAHV VANPQAEGQL QWLNRRANAL LANGVELRDN QLVVPSEGLY LIYSQVLFKG QGCPSTHVLL THTISRIAVS YQTKVNLLSA IKSPCQRETP EGAEAKPWYE PIYLGGVFQL EKGDRLSAEI NRPDYLDFAE SGQVYFGIIA F

Reconstitution:

Centrifuge vial prior to opening. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.

Storage/Stability:

This lyophilized preparation is stable at 2-4°C, but should be kept desiccated at -20°C for long term storage. Upon reconstitution, the preparation is stable for up to one week at 2-4°C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20°C to -80°C. Avoid repeated freeze/thaw cycles.